Investigational drug · Phase 2
AZD0171
Also called: MSC-1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Locally Advanced or Metastatic Solid Tumours.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AZD0171"
First trial start
2021
Dec 10, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD0171", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Solid Tumours
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD0171" as an intervention, largest first.
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05061550 · 630 participants (planned) · Start Apr 14, 2022 · Primary completion May 28, 2030
Drug: Durvalumab; Oleclumab and 10 more · For: Non-small Cell Lung Cancer
Sites: Little Rock, Arkansas; Los Angeles, California; Oakland, California · 97 sites in all
- Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04999969 · 126 participants · Start Dec 10, 2021 · Primary completion Oct 7, 2024
Drug: AZD0171; Durvalumab and 2 more · For: Locally Advanced or Metastatic Solid Tumours
Sites: La Jolla, California; Los Angeles, California; Orange, California · 34 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Mechanism-Base Pharmacokinetic-Pharmacodynamic Modeling of Cefquinome Against Streptococcus suis Serotype 2 Under Different Inoculum and Susceptibility Conditions.
Mestareehi AH · Med Sci (Basel) 2026
- From norms to action: Exploring latent profile transitions of moral self-concept and normative stances in young children's sharing behavior.
Schiele T, Valcárcel Jiménez M, Camligüney Ö, et al. · Child Dev 2026
- Case Report: An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductal adenocarcinoma with recurrence to the abdominal wall.
Enzler T, Tweedy S, Holmes I, et al. · Front Oncol 2026
- Protective effect of ketamine and bone marrow-derived mesenchymal stem cell on ovarian follicular depletion iijn a rat iijschaemia/reperfusion model: An experimental study.
Öz Gergin Ö, Pehlivan SS, Gönen ZB, et al. · J Reprod Immunol 2025
- Cellular Enhancement of Frozen Meniscus Allograft Combining Native Meniscus and Mesenchymal Stromal Cell Injections.
Struijk C, Lydon KL, Husen M, et al. · Cartilage 2025
- Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients.
Park H, Fang X, Lee H, et al. · Cytotherapy 2025
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.